CathPrint AB, owner of the CathPrint Technology® - an innovative platform for applying flexible printed circuit boards on advanced catheters enabling a very cost-efficient incorporation of electronic components within catheters, today announce the appointment of Tim Lenihan as regular board member and Chris Minar as deputy board member.
At the CathPrint Extra General Meeting of June 10 2021, Tim Lenihan was appointed board member of CathPrint AB and Chris Minar appointed deputy member of the board.
CathPrint works with partnerships for the Next Generation catheter technology platform to offer attractive and cost-efficient solutions for companies operating within the global business of advanced catheters.
Tim Lenihan is the Co-Founder of MD Start, where he has been the acting CEO of LimFlow, the 4th company created and incubated by MD Start I which focuses on critical limb ischemia and aims at restoring blood flow to the limb. More recently he was the CEO and then CTO of preCARDIA, the second company created, funded and incubated by MD Start II. Prior to founding MD Start in 2010, Tim was CEO and Founder of Contract Medical International GmbH (CMI) a contract developer and manufacturer of catheter based medical devices headquartered in Dresden Germany with facilities in both Germany and the Czech Republic.
Tim Lenihan:“I very much like the CathPrint Technology® and the simplicity of the CathPrint approach and am excited to help find new applications for the technology”
Chris Minar is president at Sand Creek Medtech, a medical device consulting company. He is also Vice President of Research and Development for Intershunt technologies. He is an endlessly curious innovation leader with broad experience across multiple industries, including close to 30 years in the medical device field, where he led the development and commercialization of products for strategic companies, contract development organizations, and start-ups.
Chris Minar:“I have gained significant experience developing products designed to leverage the potential for machine learning in both cardiology and neurology. I strongly believe that CathPrint has a unique opportunity to help maximize the potential of such devices by enabling them to have more sensors at a lower cost. I am excited to help the innovative CathPrint team realize its vision and improve patient lives.”
Agneta Edberg, Chairman of CathPrint:“I am very pleased to welcome Tim & Chris to the CathPrint Board and I am confident that they, with their highly relevant extensive experience and skills, will play an important role in supporting CathPrint in the upcoming phase of commercializing the CathPrint Technology®”